Fexofenadine: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

1 : 1 mixture (racemate)
Systematic (IUPAC) name

methyl)-1-piperidyl]butyl]phenyl]-2- methyl-propanoic acid

CAS number 83799-24-0
ATC code R06A626
PubChem  ?
ChemSpider 3231
Chemical data
Formula C 32H39NO4  
Mol. mass 501.656
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability Not yet established
Protein binding 60-70%
Metabolism Hepatic (5% of dose)
Half life 14.4 hours
Excretion Feces (~80%) and urine (~11%) as unchanged drug
Therapeutic considerations
Pregnancy cat. C (US)
B2 (Australia)
Legal status Prescription Only (US, UK)
OTC (Canada, Australia)
Routes Oral
 Yes check.svgY(what is this?)  (verify)

Fexofenadine (Allegra, Telfast, Fastofen, Tilfur) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine (brand names include Triludan and Seldane), an antihistamine with potentially serious contraindications. Fexofenadine, like other second and third-generation antihistamines, does not readily cross the blood-brain barrier, and so causes less drowsiness than first-generation histamine-receptor antagonists. It works by being an antagonist to the H1 receptor.[1]

It has been described as both second-generation[2] and third-generation.[3]



Fexofenadine is indicated for the relief from physical symptoms associated with seasonal allergic rhinitis and treatment of chronic idiopathic urticaria. It is not a therapeutic drug and does not cure but rather prevents the aggravation of rhinitis and urticaria and reduces the severity of the symptoms providing much relief from repeated sneezing, runny nose, itchy eyes and general body fatigue caused by rhinitis and urticaria. It is a safe and easy to use drug available in doses as indicated below.


  • Chronic idiopathic urticaria: Children 6 months to < 2 years: 15 mg twice daily
  • Chronic idiopathic urticaria, seasonal allergic rhinitis:
    • Children 2–11 years: 30 mg twice daily
    • Children ≥ 12 years and Adult: 60 mg twice daily or 180 mg once daily
    • Elderly: Starting dose: 60 mg once daily;


Administer with water only; do not administer with fruit juices. Shake suspension well before use.

Dosage forms

  • Suspension: 6 mg/mL (30 mL, 300 mL) [raspberry cream]
  • Tablet: 30 mg, 60 mg, 180 mg

Common side effects

  • Nausea
  • Dizziness
  • Vomiting
  • Weakness
  • Drowsiness, sleepiness
  • Fatigue
  • Diarrhea
  • Unusual bowel movements
  • Headache
  • Aggression
  • Fever


Reports of fexofenadine overdose are infrequent, and because of this, the effects are not well established. No deaths occurred in testing on mice, at 5000 mg/kg, which is 110 times the maximum recommended dose for an adult human. Further research shows no deaths in rats at the same concentration, which equates four hundred times the recommended dose in an adult human. Research on humans ranges from a single 800 mg dose, to a twice-daily 690 mg dose for a month, with no clinically significant adverse effects, when compared to a placebo.


The older antihistaminic agent terfenadine was found to metabolize into the related carboxylic acid, fexofenadine. Fexofenadine was found to retain all of the biological activity of its parent while giving fewer adverse reactions in patients, so terfenadine was replaced in the market by its metabolite.[4] Fexofenadine was originally synthesized in 1993 by Massachusetts-based biotechnology company Sepracor, which then sold the development rights to Hoechst Marion Roussel (now part of Sanofi-Aventis), and was later approved by the Food and Drug Administration (FDA) in 1996. AMRI holds the patents to the intermediates and production of fexofenadine HCl along with Roussel. Since that time, it has achieved blockbuster drug status with global sales of $1.87B USD in 2004 (with $1.49B USD coming from the United States). AMRI received royalty payments from Aventis that enabled the growth of AMRI.


Fexofenadine may be synthesized as shown from piperidine-4-carboxylate ester and 4-bromophenylacetonitrile.[4]

Chemical synthesis of fexofenadine

To produce the piperidine piece, two phenyl groups are first introduced using a Grignard reaction on the ester, giving a tertiary alcohol. The amine group is then alkylated with a protected aldehyde, then the aldehyde is recovered by deprotection with acid. The remaining piece of the molecule is produced by a double alkylation by iodomethane of the carbanion derived from the nitrile. The nitrile group is then hydrolyzed to a carboxylic acid. The aryl bromide is then lithiated to produce the organolithium compound, which can be coupled with the aldehyde piece to give (after workup) fexofenadine.


  1. ^ IngentaConnect - Fexofenadine, an H1-receptor antagonist, partially ...
  2. ^ Dicpinigaitis PV, Gayle YE (November 2003). "Effect of the second-generation antihistamine, fexofenadine, on cough reflex sensitivity and pulmonary function". British journal of clinical pharmacology 56 (5): 501–4. PMID 14651723. PMC 1884387. http://www.blackwell-synergy.com/openurl?genre=article&sid=nlm:pubmed&issn=0306-5251&date=2003&volume=56&issue=5&spage=501.  
  3. ^ Vena GA, Cassano N, Filieri M, Filotico R, D'Argento V, Coviello C (2002). "Fexofenadine in chronic idiopathic urticaria: a clinical and immunohistochemical evaluation". International journal of immunopathology and pharmacology 15 (3): 217–224. PMID 12575922.  
  4. ^ a b Daniel Lednicer (1999). The Organic Chemistry of Drug Synthesis. 6. New York: Wiley Interscience. pp. 38–40. ISBN 0-471-24510-0.  


  • Synthesis: J. Org. Chem. 1994, 59, 2620.
  • Biological effects: Mol. Pharmacol. 1993, 44, 1240.

External links

Got something to say? Make a comment.
Your name
Your email address